Psoriasis

Patients with psoriasis were found to have a more than 20% increased risk of developing incident venous thromboembolism (VTE) and peripheral vascular disease (PVD), with notable at-risk groups including women and those with concomitant psoriatic arthritis.

Patients with concomitant psoriasis and psoriatic arthritis (PsA) were shown to be 3.1-fold more likely to achieve complete skin clearance when treated with brodalumab vs ustekinumab after 52 weeks, with further improvements reported for quality of life (QOL).

Patients with concomitant psoriasis, nail psoriasis, and psoriatic arthritis (PsA) exhibited significant improvements in joint and disease severity symptoms, as well as quality of life (QOL) after 3 months of treatment with tumor necrosis factor-α (TNF) inhibitors of adalimumab, etanercept, or infliximab.

Use of biologics and age may influence risk of psoriatic arthritis (PsA) development in patients with psoriasis, according to findings presented at the 2021 American College of Rheumatology Annual Meeting.

Findings presented at the 2021 American College of Rheumatology Annual Meeting showed that patients with concomitant psoriasis and psoriatic arthritis (PsA) reported greater incidence of obesity, hypertension, and diabetes, as well as a higher likelihood of work inability than those with only psoriasis.

Phase 3 findings of the DISCOVER-2 trial presented at the 2021 American College of Rheumatology Annual Meeting indicated that guselkumab (Tremfya) provided long-term improvement in joint manifestations, disease activity, and physical function among patients with psoriatic arthritis who had no prior biologic treatment.

Real-world patients with moderate-to-severe psoriasis were shown to exhibit impaired efficacy with guselkumab treatment if they had history of prior biologic use, particularly anti-interleukin (IL)-17 exposure, with heavier patients linked with delayed onset of therapeutic response.

Findings of a real-world, single-center study indicated that apremilast was effective and safe long-term in the treatment of moderate-to-severe plaque psoriasis.

A greater proportion of biologic-naive patients with psoriatic arthritis treated with ixekizumab vs adalimumab achieved the combined endpoint of 100% resolution in the Psoriasis Area Severity Index and 50% or greater improvement in the American College of Rheumatology criteria at week 24 and 52.

This retrospective claims analysis found that concomitant joint disease in psoriasis is associated with greater health care resource utilization and health care costs than psoriasis alone.

Patients with inflammatory bowel disease (IBD) treated with adalimumab had greater risk of developing psoriasis than those administered infliximab, with gender and smoking incidence also linked with greater IBD risk.

Pregnant women with psoriasis were found to be at increased risk of experiencing preterm birth and Cesarean delivery, with patients undergoing anti-rheumatic treatment during their first pregnancy indicated to be at significantly greater risk.

Studies presented at Academy of Managed Care Pharmacy Nexus 2021 elucidated costs of skin treatment for workers in terms of recovery time taken and percentage of salary.

Biologic-experienced patients with psoriasis exhibited significantly improved treatment adherence and lower discontinuation, nonpersistence, and switching rates over 18 months when prescribed ixekizumab vs secukinumab.

Pediatric populations, young adults, and parents all identified differing goals and preferences of treatment for psoriasis, with the most important treatment goals overall cited as lesion prevention and reduction.

A novel formulation of calcipotriene (CAL), betamethasone dipropionate (BDP) cream was found to be more effective, provide superior quality of life, and safe in patients with psoriasis, compared with standard CAL/BDP topical suspension/gel.

Patients with psoriatic arthritis (PsA) were found to be more likely to report musculoskeletal symptoms and dermatologic issues prior to initial PsA diagnosis.

Patients with moderate to severe psoriasis were shown to achieve and maintain higher levels of complete skin clearance and quality of life when treated with brodalumab vs ustekinumab, regardless of the presence of lifestyle risk factors.

Secukinumab was associated with a high rate of short- and long-term drug survival in the treatment of patients with psoriasis, with factors such as obesity and prior biologic use linked to discontinuation of use.

Patients with a positive fecal immunochemistry test (FIT) were shown to be at significantly greater risk of developing psoriasis than those with FIT-negative tests.

Patients with periodontitis had a potential increased risk of developing psoriasis, particularly those who smoked.

Greater body surface area was shown to correlate with an increased risk of psoriatic arthritis development in patients with psoriasis, with obesity and depression also identified as risk factors.

Treatment of guselkumab was found to be safe and effective in improving health-related quality-of-life (HRQOL) and skin manifestations of patients with moderate to severe psoriasis in a real-world setting.

Medicare beneficiaries with psoriasis and psoriatic arthritis were found to pay high annual out-of-pocket (OOP) costs for treatment, which researchers attributed to rising drug prices and reliance on co-insurance for patient cost-sharing.

Discontinued use and high dosage of alpha-glucosidase inhibitors in combination with metformin was shown to increase risk of psoriasis and psoriatic arthritis in patients with type 2 diabetes compared with those given only metformin.